Edition:
United States

Pernix Therapeutics Holdings Inc (PTX.OQ)

PTX.OQ on NASDAQ Stock Exchange Global Market

3.88USD
4:00pm EDT
Change (% chg)

$0.17 (+4.58%)
Prev Close
$3.71
Open
$3.81
Day's High
$4.00
Day's Low
$3.76
Volume
106,331
Avg. Vol
102,626
52-wk High
$13.90
52-wk Low
$1.85

Latest Key Developments (Source: Significant Developments)

Pernix Therapeutics announces Q4 and full year 2016 financial results
Tuesday, 28 Mar 2017 04:01pm EDT 

Pernix Therapeutics Holdings Inc - : Pernix Therapeutics announces fourth quarter and full year 2016 financial results . Q4 revenue fell 35 percent to $30.1 million .Net loss was $86.1 million for Q4 of 2016, compared to $81.7 million in q4 of 2015.  Full Article

Pernix Therapeutics receives favorable opinion in litigation with Actavis Laboratories
Thursday, 23 Feb 2017 08:00am EST 

Pernix Therapeutics Holdings Inc : Pernix Therapeutics Holdings - received favorable opinion in litigation with actavis laboratories regarding proposed generic version of zohydro er . Pernix Therapeutics-judge entered order enjoining actavis from engaging in commercial manufacture, use, offer to sell, or sale in u.s. For zohydro er .Pernix Therapeutics-judge also entered order enjoining actavis from importation into united states of actavis' anda product before expiration of 2 patents.  Full Article

Pernix Therapeutics provides update on arbitration
Friday, 3 Feb 2017 08:00am EST 

Pernix Therapeutics Holdings Inc : Pernix therapeutics provides update on arbitration . Pernix therapeutics - pernix and gsk had been in arbitration regarding claims related to treximet asset purchase agreement and supply agreement . Is reviewing opinions, including amount of interest, and intends to work with gsk to conclude matter . Tribunal also denied pernix's claim that gsk breached its obligations under supply agreement . Pernix therapeutics - on jan 31, , arbitration tribunal issued opinions in favor of gsk, awarding it damages, fees in amount of about $35 million, plus interes .Pernix therapeutics holdings - pernix has already paid to gsk, or into an escrow account, an aggregate of $16.5 million, which will offset total award.  Full Article

Pernix Therapeutics ceases discussions on possible restructuring of capital structure
Tuesday, 27 Dec 2016 09:45am EST 

Pernix Therapeutics Holdings Inc : On Dec 26, 2016, co ceased discussions with noteholders on possible consensual restructuring of co's capital structure . Co continues to analyze various strategic alternatives to proactively address its liquidity and capital structure - SEC filing .Estimates to have cash balance in low $30 million range,additional $12 million of liquidity available in credit facility at Dec 31.  Full Article

Pernix reports reverse stock split and corporate governance enhancements
Thursday, 13 Oct 2016 08:57am EDT 

Pernix Therapeutics Holdings Inc : Pernix Therapeutics announces reverse stock split and corporate governance enhancements . Pernix Therapeutics Holdings Inc - trading on post-split basis on nasdaq commencing at open of stock market on October 14, 2016 .Pernix Therapeutics Holdings Inc- board of directors unanimously approved a reverse split of its common stock at a ratio of 1-for-10.  Full Article

Pernix Therapeutics qtrly net loss per common share $0.47
Thursday, 11 Aug 2016 04:01pm EDT 

Pernix Therapeutics Holdings Inc : Pernix therapeutics reports second quarter 2016 financial results and business update . Pernix therapeutics holdings inc q2 revenue $36.7 mln vs i/b/e/s view $40.3 mln .Pernix therapeutics holdings inc qtrly net loss per common and potential common share $0.47.  Full Article

Pernix Therapeutics announces reorganization of Senior Management Team
Tuesday, 26 Jul 2016 05:41pm EDT 

Pernix Therapeutics Holdings Inc : Says graham miao appointed CFO and President . Pernix Therapeutics announces reorganization of senior management team . Pernix Therapeutics Holdings Inc says John Sedor will assume role of Chief Executive Officer on a permanent basis .Sanjay Patel, CFO, Terence Novak, COO, and Barry Siegel, Senior Vice President and General Counsel are no longer employed by Pernix..  Full Article

Pernix Therapeutics appointed John A. Sedor as CEO
Tuesday, 26 Jul 2016 05:19pm EDT 

Pernix Therapeutics Holdings Inc : On July 21 board appointed John A. Sedor as company's chief executive officer, effective July 26, 2016 - SEC filing . On July 21, 2016, the board appointed Graham Miao as the company's president and chief financial officer .Company will pay Miao a salary of $41,750 per month.  Full Article

Pernix Therapeutics says restructuring sales force
Thursday, 7 Jul 2016 06:30am EDT 

Pernix Therapeutics Holdings Inc : Pernix therapeutics announces restructuring of sales force and operations . Pernix has reduced its total full-time work force by approximately 23 percent . Anticipates reorganization will result in an estimated annualized cost savings of about $10 million, beginning in Q3 2016 . As of Thursday, Pernix remains in compliance with all covenants in its debt facilities . Reorganization plan includes consolidation of neurology, pain sales forces under one sales management structure . Expects to take a one-time charge of approximately $2 million in Q3 of 2016 in connection with reorganization .Anticipates making its interest and principal payment on company's senior secured notes on August 1, 2016.  Full Article

Pernix Therapeutics Holdings announces positive interim results from a Phase IV study to compare Silenor and Zolpidem drugs
Thursday, 12 Nov 2015 11:15am EST 

Pernix Therapeutics Holdings:Announces positive interim results from a phase IV study to assess and compare the effects of silenor 6 mg and zolpidem 10 mg on balance, cognitive performance, and arousability.Results show silenor 6 mg is statistically significantly superior to zolpidem 10 mg on all measures analyzed.Says full study results are expected in Q1 of 2016.  Full Article

More From Around the Web